Comprehensive Clinical Evaluation Study of GLP-1RA
Recruiting now
Conditions studied: T2DM
In brief
The objective of this project is to identify the most efficacious glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of adult patients with type 2 diabetes mellitus (T2DM). In accordance with the index system and evaluation rules set forth in the Management Guidelines for Comprehensive Clinical Evaluation of Drugs, the effects of GLP-1RAs drugs in real-world settings are tracked, summarised, and analysed across six dimensions: safety, effectiveness, economy, innovation, appropriateness, and accessibility. This is done with the objective of ensuring that these drugs are fully utilised in accordance with their potential benefits. The objective is to ascertain the role of medical institutions as the principal entity responsible for the comprehensive evaluation of the clinical application of drugs and to provide data that will reduce the risk of using GLP-1RAs drugs. Moreover, the objective is to ascertain the advantages of their clinical application and to guarantee the safe and rational use of drugs for patients with type 2 diabetes mellitus. The objective of this study is to facilitate the fulfilment of medical institutions' role as the primary entity responsible for the comprehensive evaluation of the clinical application of medicines. Furthermore, the study will provide data that can be used to reduce the risk of using GLP-1RAs drugs, explore the advantages of their clinical application, and guarantee the safe and rational use of medicines for patients with type 2 diabetes.
Key facts
- Study ID
- NCT06686134
- Run by
- LI YAN
- People needed
- 492
- Starts
- 2024-07-01
- Expected to finish
- 2026-07-31
- Last updated by the study team
- 2024-11-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosed with type 2 diabetes;
- no study drug has been used in the last three months;
- Existing hypoglycemic programs include investigational drugs;
- Age ≥18 years old;
- The patient's demographic data, disease history, course records, laboratory test indicators, drug use and other information were complete;
- Sign informed consent.
You may not qualify if…
- persistent influenza, autoimmune disease, or other metabolic disease;
- There are obvious gastrointestinal diseases, gastrointestinal resection or malabsorption syndrome;
- diet drugs, glucocorticoids, drugs affecting gastrointestinal motility are being used;
- Patients with severe liver and kidney function impairment and patients with malignant tumors;
- Pregnant or lactating women.
Where it is running
- Yan Li — Jinan, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.